KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Ratio (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Equity Ratio for 16 consecutive years, with 0.32 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 46.42% to 0.32 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32 through Dec 2025, down 46.42% year-over-year, with the annual reading at 0.32 for FY2025, 46.42% down from the prior year.
  • Equity Ratio hit 0.32 in Q4 2025 for Inovio Pharmaceuticals, up from 0.11 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2021 to a low of 0.11 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.65 across 5 years, with a median of 0.7 in 2023.
  • Biggest five-year swings in Equity Ratio: soared 104.34% in 2021 and later tumbled 116.2% in 2025.
  • Year by year, Equity Ratio stood at 0.81 in 2021, then dropped by 20.83% to 0.64 in 2022, then rose by 7.59% to 0.69 in 2023, then decreased by 11.84% to 0.61 in 2024, then tumbled by 46.42% to 0.32 in 2025.
  • Business Quant data shows Equity Ratio for INO at 0.32 in Q4 2025, 0.11 in Q3 2025, and 0.42 in Q2 2025.